DK0797452T3 - Modulering af immunreaktionen - Google Patents

Modulering af immunreaktionen

Info

Publication number
DK0797452T3
DK0797452T3 DK95939341T DK95939341T DK0797452T3 DK 0797452 T3 DK0797452 T3 DK 0797452T3 DK 95939341 T DK95939341 T DK 95939341T DK 95939341 T DK95939341 T DK 95939341T DK 0797452 T3 DK0797452 T3 DK 0797452T3
Authority
DK
Denmark
Prior art keywords
molecules
immunogen
administration
immune response
ligands
Prior art date
Application number
DK95939341T
Other languages
Danish (da)
English (en)
Inventor
Douglas Thomas Fearon
Paul Walter Dempsey
Original Assignee
Univ Cambridge Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cambridge Tech filed Critical Univ Cambridge Tech
Application granted granted Critical
Publication of DK0797452T3 publication Critical patent/DK0797452T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Optical Communication System (AREA)
  • Amplifiers (AREA)
  • Holo Graphy (AREA)
  • Steroid Compounds (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
DK95939341T 1994-12-06 1995-12-06 Modulering af immunreaktionen DK0797452T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9424631A GB9424631D0 (en) 1994-12-06 1994-12-06 Modulating the immune response
PCT/GB1995/002851 WO1996017625A1 (en) 1994-12-06 1995-12-06 Modulating the immune response

Publications (1)

Publication Number Publication Date
DK0797452T3 true DK0797452T3 (da) 2002-08-19

Family

ID=10765518

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95939341T DK0797452T3 (da) 1994-12-06 1995-12-06 Modulering af immunreaktionen

Country Status (12)

Country Link
US (2) US6238670B1 (de)
EP (1) EP0797452B1 (de)
JP (1) JPH10509723A (de)
AT (1) ATE216593T1 (de)
AU (1) AU709990B2 (de)
CA (1) CA2207000A1 (de)
DE (1) DE69526521T2 (de)
DK (1) DK0797452T3 (de)
ES (1) ES2176347T3 (de)
GB (1) GB9424631D0 (de)
PT (1) PT797452E (de)
WO (1) WO1996017625A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5951976A (en) 1996-03-28 1999-09-14 Whitenead Institute For Biomedical Research Opsonin-enhanced cells, and methods of modulating an immune response to an antigen
CA2297786C (en) * 1997-08-05 2011-06-14 Vlaams Interuniversitair Instituut Voor Biotechnologie New immunoprotective influenza antigen and its use in vaccination
US7569674B2 (en) 1998-05-04 2009-08-04 Innexus Biotechnology International Limited Autophilic antibodies
GB9727512D0 (en) * 1997-12-31 1998-02-25 Adprotech Plc Fuzzy genes and their application in molecular adjuvants
CA2331258C (en) 1998-06-12 2011-09-20 Henry M. Jackson Foundation For The Advancement Of Military Medicine Enhancement of b cell activation and immunoglobulin secretion by co-stimulation of receptors for antigen and ebv gp350/220
US20050244954A1 (en) * 1998-06-23 2005-11-03 Blackburn Gary F Binding acceleration techniques for the detection of analytes
EP1001021B1 (de) 1998-09-25 2003-08-27 Wolfgang Prodinger Monoklonaler Antikörper gegen das humanen CD21 und dessen Verwendungen
GB0008582D0 (en) * 2000-04-08 2000-05-31 Adprotech Plc DNA immunization vectors
WO2001092295A2 (en) * 2000-05-30 2001-12-06 University Of Toronto Ligands for cd21 and compositions thereof for modulating immune responses
GB0025229D0 (en) * 2000-10-14 2000-11-29 Adprotech Ltd Veterinary immunisation vectors
JP2004529945A (ja) * 2001-05-17 2004-09-30 ラ ホヤ ファーマシューティカル カンパニー Ｃｄ２１を阻害する薬剤を使用して抗体媒介性病理を処置する方法
GB0204154D0 (en) * 2002-02-22 2002-04-10 Adprotech Ltd Cat immunisation vectors
CN100455600C (zh) * 2002-08-14 2009-01-28 阿维迪斯公司 包含支架,佐剂和抗原的异源多聚体化合物及其用途
JP2004222435A (ja) * 2003-01-16 2004-08-05 Fuji Heavy Ind Ltd 電気自動車の駆動装置
US9475853B2 (en) 2012-01-19 2016-10-25 Albany Medical College Fusion protein for enhancing immunogenicity of bacterial antigen/immunogen
WO2013139789A1 (en) * 2012-03-19 2013-09-26 Deutsches Krebsforschungszentrum B-cell receptor complex binding proteins containing t-cell epitopes
EP2674168A1 (de) * 2012-06-14 2013-12-18 PLS-Design GmbH Modulation von Effektor-T-Zell-Antworten durch lokale Depletion des Komplement-Faktors C3
CA2877441A1 (en) 2012-07-02 2014-01-09 Medizinische Universitat Wien Complement split product c4d for the treatment of inflammatory conditions
WO2019051443A1 (en) 2017-09-11 2019-03-14 Insideoutbio, Inc. METHODS AND COMPOSITIONS FOR IMPROVING IMMUNOGENICITY OF TUMORS
US20210403519A1 (en) 2018-11-02 2021-12-30 Insideoutbio, Inc. Methods and compositions to induce or suppress immune responses through the use of membrane bound complement split products
JP7757598B2 (ja) * 2021-11-17 2025-10-22 リパブリック オブ コリア（アニマル アンド プラント クオレンティン エージェンシー） 強力な適応免疫反応を誘導し且つ母体移行抗体の干渉を克服する組換え口蹄疫ｏ型ウイルス、及びそれを含む口蹄疫ワクチン組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
AU6355090A (en) 1989-08-23 1991-04-03 Scripps Clinic And Research Foundation Compositions and methods for detection and treatment of epstein-barr virus infection and immune disorders
US5331090A (en) * 1989-09-08 1994-07-19 California Institute Of Biological Research CR2 ligand compositions and methods for modulating immune cell functions
AU7566991A (en) 1990-03-14 1991-10-10 Biomembrane Institute, The Monoclonal antibody and immunoconjugates for the treatment and detection of b cell disorders
US6458360B1 (en) 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
DE69311764T2 (de) * 1992-05-14 1998-02-05 Polymun Scient Immunbio Forsch Peptide, die Antikörper induzieren, die genetisch divergierende HIV-1 Isolationen neutralisieren

Also Published As

Publication number Publication date
GB9424631D0 (en) 1995-01-25
PT797452E (pt) 2002-10-31
EP0797452A1 (de) 1997-10-01
WO1996017625A1 (en) 1996-06-13
ATE216593T1 (de) 2002-05-15
JPH10509723A (ja) 1998-09-22
DE69526521D1 (de) 2002-05-29
CA2207000A1 (en) 1996-06-13
US6238670B1 (en) 2001-05-29
US20020102656A1 (en) 2002-08-01
AU709990B2 (en) 1999-09-09
AU4120496A (en) 1996-06-26
ES2176347T3 (es) 2002-12-01
US6891027B2 (en) 2005-05-10
DE69526521T2 (de) 2002-12-05
EP0797452B1 (de) 2002-04-24

Similar Documents

Publication Publication Date Title
DK0797452T3 (da) Modulering af immunreaktionen
DK338587A (da) Modulsamling af antistofgener, antistoffer fremstillet derved samt anvendelse deraf
DE68924850D1 (de) Heterofunktionelle zellular immunologische reagenzien, impfstoffe daraus und verwendungsverfahren.
ATE47155T1 (de) Monoklonaler antikoerper.
ES2181734T3 (es) Ensayo inmunologico de ciclosporina.
RU93058563A (ru) Полипептиды, иммунореагент, способ определения антител, способ индукции иммунного ответа, композиции, способ получения полипептида
IE811595L (en) Synthetic peptide antigens
NO20003716L (no) Protein D for anvendelse in vitro, renset antistoff som binder proteinet, samt anvendelser derav
ATE87655T1 (de) Markierer der t-zelle aktivierung.
AU3900589A (en) Antigenic constructs of major histocompatibility complex class 1 antigens with specific carrier molecules, the preparation and use thereof
SE9103183D0 (sv) Virus-antibody complex
EP0699907A3 (de) Diagnoseverfahren, lösliches CD8-T-Zelloberflächenantigen und anti-CD8-Antikörper
WO1998025958A3 (en) Mammalian cell surface antigens comprising structural motifs characteristic of a member of the TNF ligand family
ATE71411T1 (de) Monoklonale antikoerper mit spezifitaet fuer membran-assoziierte antigene.
ATE45285T1 (de) Durch antiidiotype antikoerper induzierte immune antwort zu tumoren und viren.
IT8720842A0 (it) Analisi immunologiva stratificata impiegando anticorpi legati a particelle di trasporto per determinare la presenza di un antigene.
ATE74662T1 (de) Immunoanalysetestverfahren fuer cholesterolepoxide.
EP0363109A3 (de) Bestimmung eines chlamydialen oder gonokokkalen Antigens unter Verwendung eines positiv geladenen ionischen Bindungsträgers
EP0248534A3 (de) Verfahren zum Nachweis einer AIDS-Virus-Infektion
DK0749481T3 (da) Humaniserede monoklonale antistoffer mod human interleukin-4
DK426588A (da) Fremgangsmaade til paavisning af celleoverfladeantigen
ATE87941T1 (de) Monoklonaler antikoerper gegen ein p21-bezuegliches dodekapeptid des ras-onkogens.
DE3482924D1 (de) Reagenz zur verwendung im nachweis des antikoerpers gegen menschliche t-zellen-leukemievirusantigene.
DK528279A (da) Fremgangsmaade til isolering af hepatitis b e antigen eller antistof
DE3679926D1 (de) Nachweis von human-t-zellen-leukemievirus des typs-iii.